Literature DB >> 33176248

Recent discoveries in HIV-1 reverse transcriptase inhibitors.

Shuang-Xi Gu1, Yuan-Yuan Zhu2, Chao Wang3, Hai-Feng Wang4, Gen-Yan Liu3, Shuang Cao3, Lu Huang3.   

Abstract

HIV-1 reverse transcriptase inhibitors (RTIs) are indispensable components of highly active antiretroviral therapy (HAART), which has achieved great success in controlling AIDS epidemic in reducing drastically the morbidity and mortality of HIV-infected patients. RTIs are divided into two categories, nucleoside reverse transcriptase inhibitors (NRTIs) and nonnucleoside reverse transcriptase inhibitors (NNRTIs). In this review, the recent discoveries in NRTIs and NNRTIs, including approved anti-HIV drugs and noteworthy drug candidates in different development stages, are summarized, and their future direction is prospected.
Copyright © 2020 Elsevier Ltd. All rights reserved.

Entities:  

Year:  2020        PMID: 33176248     DOI: 10.1016/j.coph.2020.09.017

Source DB:  PubMed          Journal:  Curr Opin Pharmacol        ISSN: 1471-4892            Impact factor:   5.547


  8 in total

1.  An Alternative HIV-1 Non-Nucleoside Reverse Transcriptase Inhibition Mechanism: Targeting the p51 Subunit.

Authors:  Kwok-Fong Chan; Chinh Tran-To Su; Alexander Krah; Ser-Xian Phua; Joshua Yi Yeo; Wei-Li Ling; Peter J Bond; Samuel Ken-En Gan
Journal:  Molecules       Date:  2020-12-13       Impact factor: 4.411

2.  Editorial: Anti-infective 2020: HIV-From pathogenesis to treatment.

Authors:  Leonor Huerta
Journal:  Curr Opin Pharmacol       Date:  2020-10       Impact factor: 5.547

3.  Sampling of Protein Conformational Space Using Hybrid Simulations: A Critical Assessment of Recent Methods.

Authors:  Burak T Kaynak; James M Krieger; Balint Dudas; Zakaria L Dahmani; Mauricio G S Costa; Erika Balog; Ana Ligia Scott; Pemra Doruker; David Perahia; Ivet Bahar
Journal:  Front Mol Biosci       Date:  2022-02-04

Review 4.  Approved HIV reverse transcriptase inhibitors in the past decade.

Authors:  Guangdi Li; Yali Wang; Erik De Clercq
Journal:  Acta Pharm Sin B       Date:  2021-11-16       Impact factor: 14.903

5.  Genetic Diversity and Low Therapeutic Impact of Variant-Specific Markers in HIV-1 Pol Proteins.

Authors:  Paloma Troyano-Hernáez; Roberto Reinosa; Africa Holguín
Journal:  Front Microbiol       Date:  2022-07-14       Impact factor: 6.064

6.  Synergistic Effect by Combining a gp120-Binding Protein and a gp41-Binding Antibody to Inactivate HIV-1 Virions and Inhibit HIV-1 Infection.

Authors:  Xinling Wang; Miao Cao; Yanling Wu; Wei Xu; Qian Wang; Tianlei Ying; Lu Lu; Shibo Jiang
Journal:  Molecules       Date:  2021-03-31       Impact factor: 4.411

7.  Abacavir antiretroviral therapy and indices of subclinical vascular disease in persons with HIV.

Authors:  Claudia A Martinez; Rishi Rikhi; Mollie S Pester; Meela Parker; Alex Gonzalez; Michaela Larson; Jennifer Chavez; Armando Mendez; Jeffrey K Raines; Michael A Kolber; Ivonne H Schulman; Maria L Alcaide; Barry E Hurwitz
Journal:  PLoS One       Date:  2022-03-10       Impact factor: 3.240

8.  Molecular Dynamics Simulations of Docetaxel Adsorption on Graphene Quantum Dots Surface Modified by PEG-b-PLA Copolymers.

Authors:  Mehdi Yoosefian; Mitra Fouladi; Leonard Ionut Atanase
Journal:  Nanomaterials (Basel)       Date:  2022-03-11       Impact factor: 5.076

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.